Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Naglazyme Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C28288-A

    Naglazyme (galsulfase) Coverage Criteria for Mucopolysaccharidosis VI

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C28288-A alerts

    Get alerted when Policy C28288-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for intravenous Naglazyme (galsulfase) to treat mucopolysaccharidosis VI, including clinical, documentation, dosing, and administration requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyNaglazyme (galsulfase) Coverage Criteria for Mucopolysaccharidosis VI
    Policy CodePolicy C28288-A
    Change TypeRevised
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionObtain prior authorization and submit required diagnosis, baseline, and clinical response documentation for initial or continuation therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy revision history identifies revisions to required medical information, continuation-of-therapy criteria, and quantity requirements.

    The policy was revised from the retired enzyme replacement therapy policy for lysosomal storage disorders involving MPS I and MPS VI.

    1 mg/kgNaglazyme dose
    WeeklyDosing frequency
    12 monthsAuthorization duration
    3 months–29 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Age range
    J1458HCPCS code
    IVRoute

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when all of the following are met, including one option within each applicable clinical-measure branch.

    Initial therapy requirements

    • Diagnosis and diagnostic confirmation

      • Documented diagnosis of mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
      • ONE of the following diagnostic confirmation methods

        • Reduced fibroblast or leukocyte ARSB enzyme activity.
        • Molecular genetic testing of ARSB.
    • Baseline values

      • Baseline urinary glycosaminoglycan (GAG) levels.

        Documentation required.

      • ONE age-appropriate baseline-measure branch

        • Member 6 years of age or older

          • ONE of the following

            • 6-minute walk test (6-MWT).
            • Percent predicted forced vital capacity (FVC).
        • Member younger than 6 years

          • ONE or more of the following

            • Upper airway obstruction during sleep.
            • Cardiac status.
    • Disease manifestation

      • At least 1 qualifying MPS VI symptom

        • Gait disturbance.
        • Growth deficiency.
        • Short stature.
        • Spinal abnormalities.
        • Chest abnormalities.
        • Joint abnormalities.
        • Respiratory compromise.

    Continuation Therapy

    Covered for continuation therapy when all of the following are met.

    Continuation therapy requirements

    • Tolerability

      • The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity, including hypersensitivity reactions, anaphylaxis, or severe type III immune-mediated reactions such as membranous glomerulonephritis.
    • Positive clinical response or disease stability compared with baseline before therapy

      • Decreased urinary glycosaminoglycan (GAG) levels.Decreased from baseline

        Documentation required.

      • ONE age-appropriate clinical-response or disease-stability branch

        • Member 6 years of age or older

    Not Covered / Experimental Uses

    Other uses are not covered under this policy.

    Experimental or investigational use

    • All uses of Naglazyme (galsulfase) other than treatment of MPS VI are considered experimental or investigational and follow Molina's Off-Label policy.

    All uses of Naglazyme (galsulfase) other than treatment of mucopolysaccharidosis VI (MPS VI) are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Coding and Documentation Requirements

    Covered HCPCS CodesHCPCSCovered
    J1458Injection, galsulfase, 1 mg
    Covered Diagnosis CodesICD-10Covered
    E76.29Other mucopolysaccharidoses
    Baseline urinary glycosaminoglycan level
    Required measureBaseline urinary glycosaminoglycan (GAG) levels
    Documentation statusDocumentation is required
    Use in authorizationSubmit the baseline urinary GAG level documentation with the initial therapy request
    Age 6 years or older clinical baseline/response
    Age 6 years or older — baselineDocument a 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC)
    Continuation therapyDocument the 6-MWT and/or percent predicted FVC to show clinical response or disease stability compared with baseline

    Provider Submission Requirements

    Prior Authorization

    Initial and Renewal Authorization

    Prior authorization is required for initial and continuation therapy with Naglazyme (galsulfase) for MPS VI. Submit the required clinical documentation with each request; initial authorization and continuation authorization are each approved for 12 months when criteria are met.

    • Initial authorization: 12 months
    • Continuation authorization: 12 months
    • Submit supporting documentation with the initial request and each reauthorization request
    Documentation Required

    Qualified Prescriber Required

    Naglazyme must be prescribed by, or in consultation with, an appropriately qualified specialist. Eligible prescribers include a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, a physician specializing in lysosomal storage disorders, or a physician experienced in managing mucopolysaccharidoses.

    Disease Background

    Mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy syndrome, is an inherited lysosomal storage disorder caused by deficiency of the arylsulfatase B (ARSB) enzyme. This deficiency causes glycosaminoglycans, including dermatan sulfate and chondroitin 4-sulfate, to accumulate in cells and tissues. Galsulfase is enzyme replacement therapy intended to replace the deficient enzyme and reduce glycosaminoglycan accumulation.

    Key Definitions

    Mucopolysaccharidosis VI (MPS VI)
    Alternate nameMaroteaux-Lamy syndrome
    Inherited basisAn inherited lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (ARSB) gene
    Disease mechanismARSB deficiency causes accumulation of dermatan sulfate and chondroitin 4-sulfate glycosaminoglycans (GAGs), resulting in cellular dysfunction and clinical abnormalities
    Galsulfase
    IdentityRecombinant human N-acetylgalactosamine-4-sulfatase, also called arylsulfatase B (ARSB)
    Therapeutic roleProvides exogenous ARSB as enzyme replacement therapy for adults and pediatric patients 3 months and older with MPS VI

    Naglazyme Initial Authorization

    Naglazyme Initial Authorization

    Initial authorization for Naglazyme requires all of the following.

    Naglazyme initial authorization

    • Confirmed diagnosis

      • Documented diagnosis of mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
      • ONE of the following diagnostic confirmation methods

        • Reduced fibroblast or leukocyte ARSB enzyme activity.
        • Molecular genetic testing of ARSB.
    • Baseline measurements

    Naglazyme Continuation

    Naglazyme Continuation

    Continuation authorization requires all of the following.

    Naglazyme continuation

    • No intolerable adverse effects or drug toxicity

      • The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity, including hypersensitivity reactions, anaphylaxis, or severe type III immune-mediated reactions such as membranous glomerulonephritis.
    • Positive clinical response or disease stability compared with baseline before therapy

      • Decreased urinary glycosaminoglycan (GAG) levels.Decreased from baseline

        Documentation required.

      • ONE age-appropriate clinical-response or disease-stability branch

    Dose and Frequency

    Naglazyme (galsulfase)
    DrugNaglazyme (galsulfase)
    Dose1 mg/kg
    FrequencyOnce weekly

    Administration Site of Care

    Billing Rule

    Bill infusions under the applicable benefit

    When Naglazyme is infused in a non-hospital facility-based location, coverage should be provided under the pharmacy or medical benefit in accordance with Molina’s Site of Care program. The Specialty Medication Administration Site of Care Coverage Criteria policy applies.

    Policy Summary
    PayerMolina Healthcare
    PolicyNaglazyme (galsulfase) Coverage Criteria for Mucopolysaccharidosis VI
    Policy CodePolicy C28288-A
    Change TypeRevised
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionObtain prior authorization and submit required diagnosis, baseline, and clinical response documentation for initial or continuation therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Documentation RequirementsProvider Submission RequirementsDisease BackgroundKey DefinitionsNaglazyme Initial AuthorizationNaglazyme ContinuationDose and FrequencyAdministration Site of Care
    Growth velocity.
  1. Mental development.
  2. Forced vital capacity (FVC).
  3. Hepatosplenomegaly.
  4. 6-minute walk test.
  5. Cardiac valve abnormalities.
  6. Muscular weakness.
  7. Visual impairment.
  8. Hearing loss.
  9. Dental abnormalities or oral health challenges.
    • ONE of the following

      • 6-minute walk test (6-MWT).
      • Percent predicted forced vital capacity (FVC).
  10. Member younger than 6 years

    • ONE or more of the following

      • Decreased hepatosplenomegaly.
      • Improvement in upper airway obstruction during sleep.
      • Cardiac status.
      • Growth velocity.
      • Mental development.
      • Forced vital capacity (FVC).
      • 6-minute walk test.
  11. Measurement purposeUse age-appropriate clinical measures to establish baseline status and assess response or stability
    Under age 6 clinical baseline/response
    Required baselineDocument one or more of upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test
    Continuation responseDocument decreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, or the status of cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test
    Age applicabilityApplies to members younger than 6 years of age
    Disease symptoms
    Minimum requirementDocument at least one symptom of MPS VI
    Qualifying symptomsGait disturbance, growth deficiency, short stature, spinal, chest, or joint abnormalities, respiratory compromise, cardiac valve abnormalities, muscular weakness, visual impairment, hearing loss, or dental abnormalities and oral health challenges
    Authorization stageRequired for initial therapy authorization
    • Specialist prescribing or consultation is required
    • The consultation must address management of MPS or lysosomal storage disorders

    Unsupported block type: documentation ето

    Documentation Required

    Initial Clinical Documentation

    For initial treatment, document confirmed MPS VI (Maroteaux-Lamy syndrome) and the clinical findings supporting treatment. The diagnosis must be confirmed by reduced ARSB enzyme activity in fibroblasts or leukocytes or by molecular genetic testing of ARSB, with required baseline measures and disease symptoms documented.

    • Documented MPS VI diagnosis
    • Reduced fibroblast or leukocyte ARSB enzyme activity, or molecular genetic testing of ARSB
    • Baseline urinary glycosaminoglycan (GAG) level
    • For members age 6 years or older: 6-minute walk test (6-MWT) and/or percent predicted FVC
    • For members younger than 6 years: applicable baseline assessment such as upper-airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test
    • At least one disease symptom, such as gait disturbance, growth deficiency, skeletal or joint abnormalities, respiratory or cardiac abnormalities, muscular weakness, sensory impairment, or dental/oral health challenges
    Documentation Required

    Continuation Documentation

    For continuation therapy, document that the member has had a positive clinical response or disease stability compared with the pretherapy baseline and that there is no intolerable adverse effect or drug toxicity. Required response documentation includes decreased urinary GAG levels and an age-appropriate functional or clinical measure.

    • Prescriber attestation or clinical review finding of no intolerable adverse effects or toxicity
    • Address hypersensitivity reactions, anaphylaxis, and severe type III immune-mediated reactions when applicable
    • Decreased urinary GAG levels compared with baseline
    • For members age 6 years or older: 6-MWT and/or percent predicted FVC
    • For members younger than 6 years: decreased hepatosplenomegaly, improved upper-airway obstruction during sleep, or improvement in cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test
    Documentation Required

    Consultation Notes Required

    When Naglazyme is prescribed in consultation with a qualified specialist, submit the consultation notes with both the initial request and every reauthorization request.

    • Consultation notes must accompany the initial request when applicable
    • Consultation notes must accompany reauthorization requests when applicable
    Denial Risk

    Non-MPS VI Use

    Uses of Naglazyme (galsulfase) other than treatment of MPS VI are considered experimental or investigational and are not covered under this policy. Such requests will be handled under Molina's applicable Off-Label policy.

    • Covered indication: Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome)
    • Non-MPS VI uses are experimental/investigational
    • Refer applicable requests to Molina's Off-Label policy
    Denial Risk

    Insufficient or Inappropriate Documentation

    Molina may deny reimbursement or take other appropriate action when submitted documentation is incomplete, does not support medical necessity or a covered use, indicates investigational or experimental treatment, or demonstrates inappropriate or excessive billing or other practice.

    • Provide complete medical rationale and supporting documentation
    • Documentation must support medical necessity and a covered, non-investigational use
    • Additional documentation may be requested for coverage review, quality improvement, or fraud, waste, and abuse prevention
    Denial Risk

    Unmet Clinical Criteria

    Failure to document the required diagnosis, baseline measures, disease symptoms, continuation response, safety assessment, or other applicable clinical criteria creates a denial risk. Requests must establish confirmed MPS VI, appropriate baseline or response measures, and clinical appropriateness for the requested phase of therapy.

    • Confirmed MPS VI diagnosis with ARSB enzyme or molecular genetic evidence
    • Required baseline urinary GAG and age-appropriate clinical or functional measures for initial therapy
    • At least one qualifying MPS VI symptom for initial therapy
    • For continuation: positive response or disease stability, including decreased urinary GAG and age-appropriate clinical improvement or stability
    • No intolerable adverse effects or drug toxicity
    • Required prescriber qualification and consultation documentation when applicable
    Enzyme functionCatalyzes cleavage of the sulfate ester from terminal residues of chondroitin 4-sulfate and dermatan sulfate GAGs
  12. Baseline urinary glycosaminoglycan (GAG) levels.

    Documentation required.

  13. ONE age-appropriate baseline-measure branch

    • Member 6 years of age or older

      • ONE of the following

        • 6-minute walk test (6-MWT).
        • Percent predicted forced vital capacity (FVC).
    • Member younger than 6 years

      • ONE or more of the following

        • Upper airway obstruction during sleep.
        • Cardiac status.
        • Growth velocity.
        • Mental development.
        • Forced vital capacity (FVC).
        • Hepatosplenomegaly.
        • 6-minute walk test.
  14. Disease manifestation

    • At least 1 qualifying MPS VI symptom

      • Gait disturbance.
      • Growth deficiency.
      • Short stature.
      • Spinal abnormalities.
      • Chest abnormalities.
      • Joint abnormalities.
      • Respiratory compromise.
      • Cardiac valve abnormalities.
      • Muscular weakness.
      • Visual impairment.
      • Hearing loss.
      • Dental abnormalities or oral health challenges.
    • Member 6 years of age or older

      • ONE of the following

        • 6-minute walk test (6-MWT).
        • Percent predicted forced vital capacity (FVC).
    • Member younger than 6 years

      • ONE or more of the following

        • Decreased hepatosplenomegaly.
        • Improvement in upper airway obstruction during sleep.
        • Cardiac status.
        • Growth velocity.
        • Mental development.
        • Forced vital capacity (FVC).
        • 6-minute walk test.